A Phase 1 interventional study of KY1005 in Immune System Diseases, sponsored by Kymab Limited. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-30.
Sponsored by Kymab Limited (part of Sanofi) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Single centre, open-label, single dose, parallel group study to investigate the PK, safety and tolerability of KY1005 after subcutaneous (s.c.) and intravenous (i.v.) administration, with i.v. KY1005 as a reference treatment.
428 studies on the registry are indexed under Immune System Diseases; 86 are open to participants now.
This study's enrollment of 24 is below the median of 66 across 317 interventional studies indexed under Immune System Diseases.
Browse Immune System Diseases studies →Kymab Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.
First submitted before Kymab Limited became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of KY1005 by i.v. infusion
Drug: KY1005
Single lower dose KY1005 by s.c. injection
Drug: KY1005
Single higher dose KY1005 by s.c. injections
Drug: KY1005
A human anti-OX40 ligand monoclonal antibody
Maximum observed concentration (Cmax) after infusion
Time frame: Baseline to day 92
Time at which Cmax is observed after infusion (tmax)
Time frame: Baseline to day 92
Area under the concentration time curve from time 0 to last observation (AUC 0-t)
Time frame: Baseline to day 92
Area under the concentration time curve from time 0 to infinity (AUC0-inf)
Time frame: Baseline to day 92
Systemic clearance after i.v. infusion (CL)
Time frame: Baseline to day 92
Apparent systemic clearance after s.c. injection (CL/F)
Time frame: Baseline to day 92
Volume of distribution during the terminal phase after i.v. infusion (Vz)
Time frame: Baseline to day 92
Apparent volume of distribution after s.c. injection (Vz/F)
Time frame: Baseline to day 92
Steady-state volume of distribution after i.v. infusion (Vss)
Time frame: Baseline to day 92
Weight-normalised Vss and Vz
Time frame: Baseline to day 92
Half-life t½
Time frame: Baseline to day 92
Dose-normalised Cmax (Cmax/D) following s.c. and i.v. administration
Time frame: Baseline to day 92
Absolute bioavailability (F) calculated as the ratio of AUC0-inf/D after i.v. and s.c. infusion
Time frame: Baseline to day 92
Dose-normalised AUC0-inf (AUC0-inf/D) following s.c. and i.v. administration
Time frame: Baseline to day 92
Occurrence of TEAE
Time frame: Baseline to day 92
Occurrence of TESAE
Time frame: Baseline to day 92
Occurrence of local injection site reactions
Time frame: Baseline to day 92
Changes in blood pressure mmHg (as a measure of safety and tolerability)
Time frame: Baseline to day 92
Changes in respiratory rate measured as breaths per minute (as a measure of safety and tolerability)
Time frame: Baseline to day 92
Changes in heart rate bpm (as a measure of safety and tolerability)
Time frame: Baseline to day 92
Changes in tympanic temperature °C (as a measure of safety and tolerability)
Time frame: Baseline to day 92
Changes in electrocardiograms PR, QR, QRS and QT intervals (as a measure of safety and tolerability)
Time frame: Baseline to day 92
Serum anti-KY1005 antibody titres
Time frame: Baseline to day 92
Incidence of anti-KY1005 antibodies
Time frame: Baseline to day 92
Ran from Jul 2020 to primary completion in Nov 2020, 4 months.
Of 25 industry-sponsored phase 1 interventional studies under Immune System Diseases, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 32. This study's 4 months is below that.
Counting every sponsor, half of 39 studies reached it within 29 months; a quarter within 5 and three quarters within 69.
Immune System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlitelimab